PEGCYTE INJ PFS

About

Pegfilgrastim is a pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF), a cytokine that plays a vital role in the production, maturation, and activation of neutrophils. Neutrophils are a type of white blood cell essential for the body's immune defense against bacterial and fungal infections. The pegylation process extends the drug's half-life, allowing for a single dose per chemotherapy cycle, which offers significant convenience compared to daily G-CSF formulations. Its primary therapeutic use is to reduce the incidence of febrile neutropenia, a serious and potentially life-threatening complication of myelosuppressive chemotherapy in patients with non-myeloid malignancies. By stimulating neutrophil recovery, pegfilgrastim helps to minimize the risk of infection, enabling patients to maintain their planned chemotherapy schedules and improve overall treatment outcomes.

Uses

• Prevention of febrile neutropenia
• Reduction of infection risk during chemotherapy
• Support for myelosuppressive chemotherapy
• Mobilization of hematopoietic stem cells (off-label)

Directions For Use

Administer as a single subcutaneous injection once per chemotherapy cycle, at least 24 hours after chemotherapy.

Benefits

• Reduces incidence of febrile neutropenia
• Decreases risk of infection
• Allows for on-schedule chemotherapy
• Convenient single-dose per cycle
• Improves patient safety during chemotherapy
• Enhances neutrophil recovery

Side Effects

• Bone pain
• Myalgia
• Nausea
• Fatigue
• Headache
• Injection site reactions
• Splenic rupture (rare but serious)
• Acute respiratory distress syndrome (ARDS) (rare)
• Allergic reactions
• Glomerulonephritis (rare)
• Leukocytosis
• Thrombocytopenia (paradoxical)

Safety Measures

• Alcohol - No specific interaction, but general health advice applies; avoid excessive intake.
• Pregnancy - Use only if potential benefit justifies potential risk to the fetus; animal studies show adverse effects.
• Breastfeeding - Unknown if excreted in human milk; caution advised, weigh benefits against risks.
• Liver - No specific dose adjustment required for hepatic impairment.
• Kidney - No specific dose adjustment required for renal impairment.
• Lung - Monitor for pulmonary symptoms (e.g., cough, fever, dyspnea) as ARDS and interstitial lung disease have been reported.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.